Highly Specific L-Type Amino Acid Transporter 1 Inhibition by JPH203 as a Potential Pan-Cancer Treatment

被引:10
作者
Achmad, Arifudin [1 ,2 ]
Lestari, Shinta [3 ]
Holik, Holis Abdul [3 ]
Rahayu, Driyanti [3 ]
Bashari, Muhammad Hasan [2 ,4 ]
Faried, Ahmad [5 ]
Kartamihardja, Achmad Hussein Sundawa [1 ]
机构
[1] Univ Padjadjaran, Fac Med, Dept Nucl Med & Mol Theranost, Hasan Sadikin Gen Hosp, Bandung 40161, Indonesia
[2] Padjadjaran State Univ, Fac Med, Oncol & Stem Cell Working Grp, Bandung 40161, Indonesia
[3] Univ Padjadjaran, Fac Pharm, Dept Pharmaceut Anal & Med Chem, Sumedang 45363, Indonesia
[4] Univ Padjadjaran, Fac Med, Dept Basic Med Sci, Div Pharmacol & Therapy, Bandung 40161, Indonesia
[5] Padjadjaran State Univ, Fac Med, Dept Neurosurg, Hasan Sadikin Gen Hosp, Bandung 40161, Indonesia
关键词
cancer; JPH203; LAT1; targeted drug; amino acid metabolism; PROGNOSTIC-SIGNIFICANCE; CD98; EXPRESSION; LAT1; ASCT2; CHEMOTHERAPY; HALLMARKS; XCT;
D O I
10.3390/pr9071170
中图分类号
TQ [化学工业];
学科分类号
0817 ;
摘要
Accelerated cancer cell growth requires a massive intake of amino acids. Overexpression of L-type (large) amino acid transporter 1 (LAT1) on the cancer cell membrane facilitates such a demand, which is limited in normal organs. Therefore, LAT1 overexpression is ideal as a molecular cancer therapeutic target. JPH203, a LAT1-selective non-transportable blocker, had demonstrated LAT1 inhibition in <10 mu M IC50 values and effectively suppressed cancer cell growth in studies involving several types of cancer cell lines and tumor xenograft models. A limited phase I clinical trial was performed on five different solid tumors and showed that JPH203 is well-tolerated and has a promising activity for the treatment of bile duct cancer. This review details the development and prospect of JPH203 as a LAT1-targeting cancer therapy.
引用
收藏
页数:15
相关论文
共 62 条
[1]   The diagnostic performance of 18F-FAMT PET and 18F-FDG PET for malignancy detection: a meta-analysis [J].
Achmad, Arifudin ;
Bhattarai, Anu ;
Yudistiro, Ryan ;
Heryanto, Yusri Dwi ;
Higuchi, Tetsuya ;
Tsushima, Yoshito .
BMC MEDICAL IMAGING, 2017, 17
[2]  
[Anonymous], 2019, Eur Soc Med, V7, DOI [10.18103/mra.v7i12.2014, DOI 10.18103/MRA.V7I12.2014]
[3]   Amino Acid Transporters in Cancer and Their Relevance to "Glutamine Addiction": Novel Targets for the Design of a New Class of Anticancer Drugs [J].
Bhutia, Yangzom D. ;
Babu, Ellappan ;
Ramachandran, Sabarish ;
Ganapathy, Vadivel .
CANCER RESEARCH, 2015, 75 (09) :1782-1788
[4]   The great escape: tumour cell plasticity in resistance to targeted therapy [J].
Boumahdi, Soufiane ;
de Sauvage, Frederic J. .
NATURE REVIEWS DRUG DISCOVERY, 2020, 19 (01) :39-56
[5]  
Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609]
[6]   Timeline - Chemotherapy and the war on cancer [J].
Chabner, BA ;
Roberts, TG .
NATURE REVIEWS CANCER, 2005, 5 (01) :65-72
[7]   Targeted Engineering of Medicinal Chemistry for Cancer Therapy: Recent Advances and Perspectives [J].
Chen, Weihua ;
Sun, Zhen ;
Lu, Lehui .
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2021, 60 (11) :5626-5643
[8]   JPH203, a selective L-type amino acid transporter 1 inhibitor, induces mitochondria-dependent apoptosis in Saos2 human osteosarcoma cells [J].
Choi, Dae Woo ;
Kim, Do Kyung ;
Kanai, Yoshikatsu ;
Wempe, Michael F. ;
Endou, Hitoshi ;
Kim, Jong-Keun .
KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY, 2017, 21 (06) :599-607
[9]   Inhibition of the amino-acid transporter LAT1 demonstrates anti-neoplastic activity in medulloblastoma [J].
Cormerais, Yann ;
Pagnuzzi-Boncompagni, Marina ;
Schrotter, Sandra ;
Giuliano, Sandy ;
Tambutte, Eric ;
Endou, Hitoshi ;
Wempe, Michael F. ;
Pages, Gilles ;
Pouyssegur, Jacques ;
Picco, Vincent .
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2019, 23 (04) :2711-2718
[10]  
Endou H, 2008, U.S. Patent, Patent No. [7345086B2, 7345086]